Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs Eli Lilly And Co — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.5, while Eli Lilly And Co trades at $1,215 (market cap $1.10T). The key difference: Eli Lilly And Co pays a 0.56% dividend while State Street SPDR Bloomberg 1-3 Month T-Bill ETF pays none. Which is the better fit depends on your goals.
| BIL | LLY | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $91.77 | $1.24K |
52-Week Low | $91.27 | $639.43 |
Market Cap | — | $1.10T |
Enterprise Value | — | $1.14T |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIL trades at $91.48 with minimal daily movement (+0.03%), showing stability amid market volatility. The ETF maintains consistent dividend distributions of $0.27 per share quarterly, with recent institutional buying activity indicating professional confidence. Technical indicators show bearish momentum with moving averages signaling caution, though oscillators suggest potential stabilization near current levels.
As a short-term Treasury ETF, BIL offers capital preservation and steady income through Treasury bill exposure. Key risks include interest rate sensitivity and inflation pressures affecting Treasury yields. The fund's defensive positioning appeals to risk-averse investors seeking liquidity and minimal credit risk in uncertain markets.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
